Changchun high-tech stock fluctuates as performance concerns arise

Changchun High & New Technology Industry Group's A-share stock (000661) recorded an abnormal fluctuation, with its closing price deviation reaching 20.00% over two consecutive trading days on September 1st and 2nd, 2025. The company confirmed that previously disclosed information remains accurate, with no need for correction or supplement. Market attention has recently focused on the company's 2025 half-year results, innovative drug business, and the proposed issuance of H-shares.

For the first half of 2025, the company reported revenue of CNY 6.603 bn, a 0.54% decrease year-over-year, and a net profit attributable to shareholders of CNY 983 m, a 42.85% decrease from the previous year. The company reiterated that innovative drug development involves long cycles, high investment, and significant uncertainty, advising investors to consider the associated risks.

On August 28, 2025, the board of directors approved the proposed issuance of H-shares and their listing on the main board of the Hong Kong Stock Exchange, with related procedures currently underway. The company stated no undisclosed major information, no changes in operations or external environment, and confirmed no trading activity by the controlling shareholder or their consistent actors during the abnormal stock fluctuation period.